Can Traders Find Even More Inspiration? (NSPR)

InspireMD (OTC: NSPR) released its fiscal year 2012 financials this morning. Due to the transition of a different month for the fiscal year end, financial comparisons were based on a corresponding six-month period in 2011. The results showed a $600,000 decline in revenues to $2.1 million because of a large shipment in 2011 that accounted for over half of the revenues in that year. Operating expenses jumped by 75% to $7.9 million. The bottom line for the six months ended with a loss of $7.1 million, or $0.10 per weighted average share.

The company also highlighted some recent activities in the report. InspireMD raised $11 million during the sixth month period through a convertible debt offering. The company also completed enrollment in a 433-patient master trial of its MGuard embolic prevention stent ahead of schedule. Inspire will present the findings from the master study next month at the Transcatheter Cardiovascular Therapeutics conference in Miami, Florida.

Since the first of June, buyers willing to pay higher prices have flowed steadily into the stock. After hitting an annual low of $0.60 three months ago, the stock has rarely ended a trading session in the red with share prices climbing over 200%. After the company announced positive results from the MGuard stent master trial on August 20, 2012, the stock has doubled in price from $1.25. It is now knocking on the door of its 52-week high established last November when shares traded for $2.59. The company also gained exposure this summer by presenting at several conferences including the Harvard Investors Group held in New York during the month of June. The question facing traders today is whether the recently released financial results and company updates will inspire buyers to keep up the pace.

On the opening bell this morning, shares traded for $2.36, or basically where they ended the session on Tuesday. For most of the day, traders could not make up their minds whether to buy or sell the stock. In the first 30 minutes of the trading session, the stock in a 10 cents range from $2.43 to an intraday low of $2.33. After digesting their lunch, buyers seemed to find the energy to take the stock higher in the final hours of the trading session. The stock ended the day with a gain of 4% to finish up a dime at a price of $2.45. The 834,000 shares exchanging hands during the trading session outpaced the 231,000 shares traded on an average day.

A check of Stockreads.com and Stockpromoters.com show no promotional activity at all for the company. Though little has been said on Twitter, @Pennies4Stocks noted last week the recent doubling in price since August.

The Tel Aviv, Israel, company focuses on developing and commercializing its stent technology known as MGuard. Besides using the technology in patients with acute myocardial infarction and saphenous vein graft coronary procedures, InspireMD also wants to develop its technology for other cardio and vascular interventions. The company was founded in 2008.

 

 

 

 

 

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Alan Masterson

Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@wallstreetpr.com) or his Google+ page (https://plus.google.com/103338576216002376250).

Recent Stories

SignUp Now For Our Featured Newsletter